Word is Pfizer is considering selling or spinning off its consumer health operations and that it could bring in $14 billion or more.

Seeking to overcome a wave of public and governmental attention to its EpiPen, Mylan is working to finalize its $465 million settlement with the federal…

Another quarter, another slump for Gilead’s hepatitis C franchise, with sales down 31%. Despite better-than-expected overall revenue, market-watchers zeroed on…

Earlier this year, Valeant reportedly turned down a takeover offer from Takeda and TPG. Now, the Japanese drugmaker wants to snag just one piece of the…

After missing out on a much-desired Medivation buy, Sanofi CEO Olivier Brandicourt told analysts Friday that he's still shopping for M&A, and not just…

Some of Bayer's Big Pharma rivals would lash themselves to a mast during a storm to post sales growth as high as 7%. But that's just what Bayer did,…

Has Novartis put its plans to unload its $12 billion-plus Roche stake on hold? Sonntagszeitung says the sale has been “iced” because Novartis has no M&A…

The specialty pharmacy space has been in somewhat of a rut when it comes to M&A--but that won’t last, Moody’s says.

M&A